Schedule 13G ownership disclosure

Seelos Therapeutics Inc (US)

Common Stock, par value $0.001 per share · CUSIP: 81577F406

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Lind Global Fund II LP

    Shares: 0 · Class: 0%

  • Lind Global Partners II LLC

    Shares: 0 · Class: 0%

  • Lind Global Asset Management V, LLC

    Shares: 0 · Class: 0%

  • EASTON JEFF

    Shares: 0 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-25-000809
Form type
SCHEDULE 13G/A
Filer
Lind Global Fund II LP
CIK
CIK 1871665
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub